Addex Therapeutics to Report Q1 2026 Financial Results on June 25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Earnings Announcement: Addex Therapeutics will report its Q1 2026 financial results on June 25, 2026, with CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev providing a business update during a teleconference and webcast, which is expected to bolster market confidence in the company's future prospects.
- Pipeline Update: The lead drug candidate, dipraglurant, is under evaluation for its potential in brain injury recovery, including post-stroke and traumatic brain injury, which could enhance the company's market position in the neurological disorders sector.
- Partnership Progress: Addex's collaboration with Indivior is advancing, as Indivior has selected a GABAB PAM drug candidate for development in substance use disorders and successfully completed IND enabling studies, potentially providing Addex with a new revenue stream.
- Investment and Equity Structure: Addex holds a 20% equity interest in Neurosterix US Holdings LLC, a private company advancing several allosteric modulator programs, including M4 PAM and mGlu7 NAM, demonstrating Addex's diversified investment strategy in the neuropsychiatric disorders space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADXN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Addex Therapeutics to Report Q1 2026 Financial Results and Corporate Update
- Earnings Release Schedule: Addex Therapeutics is set to announce its Q1 2026 financial results on June 25, 2026, during which it will provide a business update and product pipeline review, likely generating positive investor sentiment.
- Executive Participation: CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will host a teleconference at 16:00 CEST, expected to attract significant investor interest and enhance the company's transparency.
- Pipeline Progress: Addex's lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, particularly post-stroke and traumatic brain injury, indicating the company's potential in neurological disorder treatments.
- Strategic Partnerships and Investments: Addex's collaboration with Indivior on a GABAB PAM drug candidate has successfully completed IND enabling studies, while the company is also advancing an independent GABAB PAM program for chronic cough, showcasing its diversified strategy in neuropharmaceutical development.
See More
Addex Therapeutics to Report Q1 2026 Financial Results on June 25
- Earnings Announcement: Addex Therapeutics will report its Q1 2026 financial results on June 25, 2026, with CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev providing a business update during a teleconference and webcast, which is expected to bolster market confidence in the company's future prospects.
- Pipeline Update: The lead drug candidate, dipraglurant, is under evaluation for its potential in brain injury recovery, including post-stroke and traumatic brain injury, which could enhance the company's market position in the neurological disorders sector.
- Partnership Progress: Addex's collaboration with Indivior is advancing, as Indivior has selected a GABAB PAM drug candidate for development in substance use disorders and successfully completed IND enabling studies, potentially providing Addex with a new revenue stream.
- Investment and Equity Structure: Addex holds a 20% equity interest in Neurosterix US Holdings LLC, a private company advancing several allosteric modulator programs, including M4 PAM and mGlu7 NAM, demonstrating Addex's diversified investment strategy in the neuropsychiatric disorders space.
See More
Addex Therapeutics Announces 2026 Annual General Meeting Details
- AGM Timing: Addex Therapeutics has announced that its 2026 Annual General Meeting will take place on June 29, 2026, at 11:00 am CEST at Campus Biotech in Geneva, with doors opening at 10:30 am, aimed at reviewing and approving the Annual Report and Financial Statements for the fiscal year 2025.
- Board Member Elections: The meeting will include re-elections for board members, including Chairman Vincent Lawton, ensuring continuity and stability in corporate governance, which is crucial for maintaining investor confidence.
- Capital Structure Adjustments: The AGM will discuss amendments to the Articles of Association, including an increase in the capital band and conditional share capital, which may support future financing and expansion, reflecting the company's strategic planning for growth.
- Compensation Report Review: A consultative vote on the Compensation Report for the fiscal year 2025 will also be held, ensuring that management compensation aligns with company performance, aimed at enhancing governance standards and transparency.
See More
Addex Therapeutics Reports FY 2025 Net Loss
- Financial Decline: Addex Therapeutics reported a net loss of CHF 6.7 million for FY 2025, contrasting sharply with a net profit of CHF 7.1 million in 2024, indicating a significant deterioration in profitability that may undermine investor confidence.
- Revenue Source Changes: While specific revenue sources for 2025 were not disclosed, the reported loss suggests potential challenges in product sales or research progress, which could adversely affect future cash inflows.
- Market Reaction Expectations: Given the poor financial performance, Addex's stock price may experience negative pressure, prompting investors to closely monitor the company's future strategic adjustments and profit recovery plans.
- Need for Strategic Reevaluation: In light of ongoing financial losses, Addex may need to reassess its R&D pipeline and market strategies to ensure sustainable growth in the highly competitive biopharmaceutical industry.
See More
Addex Therapeutics Reports 2025 Financial Results and Strategic Developments
- R&D Progress: Addex Therapeutics' GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity across multiple disease models, indicating its potential for clinical application and possibly opening new revenue streams for the company.
- Strategic Collaboration: The exclusive licensing agreement with Sinntaxis aims to leverage mGlu5 NAM for brain injury recovery, further enhancing Addex's competitive edge in the neurological disorder treatment space.
- Financial Position: As of December 31, 2025, cash reserves stood at CHF 1.6 million, significantly down from 2024, reflecting the company's cash burn in R&D and investment activities, which may impact future operational flexibility.
- Loss Overview: The net loss for 2025 reached CHF 6.7 million, a stark contrast to a net profit of CHF 7.1 million in 2024, primarily due to reduced revenues from the Neurosterix transaction, highlighting financial pressures on the company.
See More
Addex Reports Promising Preclinical Data for Chronic Cough Treatment
- Promising Preclinical Data: Addex Therapeutics announced that its GABAB positive allosteric modulator demonstrated significant antitussive activity in a bleomycin-induced idiopathic pulmonary fibrosis chronic cough model, indicating potential for improving patient quality of life.
- Efficacy and Safety Profile: In studies involving non-human primates, the compound exhibited robust antitussive efficacy without significant changes in respiratory rate or body temperature throughout the treatment, supporting its safety for chronic administration.
- Improved Lung Pathology: Compared to untreated animals, the treatment group showed significant reductions in Ashcroft scores and affected lung tissue percentages at both Day 7 and Day 28, indicating a positive impact on fibrosis and further validating its clinical application prospects.
- Strong Market Demand: Chronic cough remains a significant unmet medical need among patients with idiopathic pulmonary fibrosis, and Addex's research findings could provide new treatment options in this area, enhancing its competitive position in the market.
See More
Addex Therapeutics to Report Q1 2026 Financial Results and Corporate Update
- Earnings Release Schedule: Addex Therapeutics is set to announce its Q1 2026 financial results on June 25, 2026, during which it will provide a business update and product pipeline review, likely generating positive investor sentiment.
- Executive Participation: CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will host a teleconference at 16:00 CEST, expected to attract significant investor interest and enhance the company's transparency.
- Pipeline Progress: Addex's lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, particularly post-stroke and traumatic brain injury, indicating the company's potential in neurological disorder treatments.
- Strategic Partnerships and Investments: Addex's collaboration with Indivior on a GABAB PAM drug candidate has successfully completed IND enabling studies, while the company is also advancing an independent GABAB PAM program for chronic cough, showcasing its diversified strategy in neuropharmaceutical development.
See More
Addex Therapeutics to Report Q1 2026 Financial Results on June 25
- Earnings Announcement: Addex Therapeutics will report its Q1 2026 financial results on June 25, 2026, with CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev providing a business update during a teleconference and webcast, which is expected to bolster market confidence in the company's future prospects.
- Pipeline Update: The lead drug candidate, dipraglurant, is under evaluation for its potential in brain injury recovery, including post-stroke and traumatic brain injury, which could enhance the company's market position in the neurological disorders sector.
- Partnership Progress: Addex's collaboration with Indivior is advancing, as Indivior has selected a GABAB PAM drug candidate for development in substance use disorders and successfully completed IND enabling studies, potentially providing Addex with a new revenue stream.
- Investment and Equity Structure: Addex holds a 20% equity interest in Neurosterix US Holdings LLC, a private company advancing several allosteric modulator programs, including M4 PAM and mGlu7 NAM, demonstrating Addex's diversified investment strategy in the neuropsychiatric disorders space.
See More
Addex Therapeutics Announces 2026 Annual General Meeting Details
- AGM Timing: Addex Therapeutics has announced that its 2026 Annual General Meeting will take place on June 29, 2026, at 11:00 am CEST at Campus Biotech in Geneva, with doors opening at 10:30 am, aimed at reviewing and approving the Annual Report and Financial Statements for the fiscal year 2025.
- Board Member Elections: The meeting will include re-elections for board members, including Chairman Vincent Lawton, ensuring continuity and stability in corporate governance, which is crucial for maintaining investor confidence.
- Capital Structure Adjustments: The AGM will discuss amendments to the Articles of Association, including an increase in the capital band and conditional share capital, which may support future financing and expansion, reflecting the company's strategic planning for growth.
- Compensation Report Review: A consultative vote on the Compensation Report for the fiscal year 2025 will also be held, ensuring that management compensation aligns with company performance, aimed at enhancing governance standards and transparency.
See More
Addex Therapeutics Reports FY 2025 Net Loss
- Financial Decline: Addex Therapeutics reported a net loss of CHF 6.7 million for FY 2025, contrasting sharply with a net profit of CHF 7.1 million in 2024, indicating a significant deterioration in profitability that may undermine investor confidence.
- Revenue Source Changes: While specific revenue sources for 2025 were not disclosed, the reported loss suggests potential challenges in product sales or research progress, which could adversely affect future cash inflows.
- Market Reaction Expectations: Given the poor financial performance, Addex's stock price may experience negative pressure, prompting investors to closely monitor the company's future strategic adjustments and profit recovery plans.
- Need for Strategic Reevaluation: In light of ongoing financial losses, Addex may need to reassess its R&D pipeline and market strategies to ensure sustainable growth in the highly competitive biopharmaceutical industry.
See More
Addex Therapeutics Reports 2025 Financial Results and Strategic Developments
- R&D Progress: Addex Therapeutics' GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity across multiple disease models, indicating its potential for clinical application and possibly opening new revenue streams for the company.
- Strategic Collaboration: The exclusive licensing agreement with Sinntaxis aims to leverage mGlu5 NAM for brain injury recovery, further enhancing Addex's competitive edge in the neurological disorder treatment space.
- Financial Position: As of December 31, 2025, cash reserves stood at CHF 1.6 million, significantly down from 2024, reflecting the company's cash burn in R&D and investment activities, which may impact future operational flexibility.
- Loss Overview: The net loss for 2025 reached CHF 6.7 million, a stark contrast to a net profit of CHF 7.1 million in 2024, primarily due to reduced revenues from the Neurosterix transaction, highlighting financial pressures on the company.
See More
Addex Reports Promising Preclinical Data for Chronic Cough Treatment
- Promising Preclinical Data: Addex Therapeutics announced that its GABAB positive allosteric modulator demonstrated significant antitussive activity in a bleomycin-induced idiopathic pulmonary fibrosis chronic cough model, indicating potential for improving patient quality of life.
- Efficacy and Safety Profile: In studies involving non-human primates, the compound exhibited robust antitussive efficacy without significant changes in respiratory rate or body temperature throughout the treatment, supporting its safety for chronic administration.
- Improved Lung Pathology: Compared to untreated animals, the treatment group showed significant reductions in Ashcroft scores and affected lung tissue percentages at both Day 7 and Day 28, indicating a positive impact on fibrosis and further validating its clinical application prospects.
- Strong Market Demand: Chronic cough remains a significant unmet medical need among patients with idiopathic pulmonary fibrosis, and Addex's research findings could provide new treatment options in this area, enhancing its competitive position in the market.
See More
